Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors

Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors

Abstract Coronavirus disease 2019 (COVID-19) is a recent pandemic that caused serious global emergency. To identify new and effective therapeutics, we employed a drug repurposing approach. The poly (ADP ribose) polymerase inhibitors were used for this purpose and were repurposed against the main pro...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Shailima Rampogu, Tae Sung Jung, Min Woo Ha, Keun Woo Lee
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	Nature Portfolio 2023-06-01
Sraith:	Scientific Reports
Rochtain ar líne:	https://doi.org/10.1038/s41598-023-36342-7

Míreanna comhchosúla

Virtual screening, molecular docking, molecular dynamics simulations and free energy calculations to discover potential DDX3 inhibitors
de réir: Shailima Rampogu, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Explicit molecular dynamics simulation studies to discover novel natural compound analogues as Mycobacterium tuberculosis inhibitors
de réir: Shailima Rampogu, et al.
Foilsithe / Cruthaithe: (2023-02-01)

Computational Approaches to Discover Novel Natural Compounds for SARS‐CoV‐2 Therapeutics
de réir: Dr. Shailima Rampogu, et al.
Foilsithe / Cruthaithe: (2021-05-01)

Computational repurposing of asthma drugs as potential inhibitors of SARS-CoV-2 Mpro
de réir: A. Hussain, et al.
Foilsithe / Cruthaithe: (2022-04-01)

Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase
de réir: Syed Hani Abidi, et al.
Foilsithe / Cruthaithe: (2021-05-01)

Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations
de réir: Shailima Rampogu, et al.
Foilsithe / Cruthaithe: (2018-03-01)

Correction to: Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations
de réir: Shailima Rampogu, et al.
Foilsithe / Cruthaithe: (2019-12-01)

Multi-Targeted Approaches and Drug Repurposing Reveal Possible SARS-CoV-2 Inhibitors
de réir: Khalid Mashay Alanazi, et al.
Foilsithe / Cruthaithe: (2021-12-01)

Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics
de réir: Shraddha Parate, et al.
Foilsithe / Cruthaithe: (2021-03-01)

From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease
de réir: Matthias Göhl, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
de réir: Pietro Delre, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Inhibitors of SARS-CoV-2 PLpro
de réir: Dale J. Calleja, et al.
Foilsithe / Cruthaithe: (2022-04-01)

Ligand-Based and Structured-Based In Silico Repurposing Approaches to Predict Inhibitors of SARS-CoV-2 Mpro Protein
de réir: Alfredo Juárez-Saldívar, et al.
Foilsithe / Cruthaithe: (2020-11-01)

In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Nucleocapsid Through Molecular Docking-Based Drug Repurposing
de réir: Rukhsar Afreen, et al.
Foilsithe / Cruthaithe: (2022-05-01)

Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro Inhibitors
de réir: Dale J. Calleja, et al.
Foilsithe / Cruthaithe: (2022-04-01)

Potential SARS-CoV-2 nonstructural proteins inhibitors: drugs repurposing with drug-target networks and deep learning
de réir: Shayan K. Azmoodeh, et al.
Foilsithe / Cruthaithe: (2022-04-01)

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
de réir: Jeremy D Baker, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants
de réir: Katherine E. Zarn, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants.
de réir: Katherine E Zarn, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2
de réir: Renata Abel, et al.
Foilsithe / Cruthaithe: (2020-12-01)

Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug
de réir: Camilla Isgrò, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel <i>In Silico</i> Method
de réir: Milan Sencanski, et al.
Foilsithe / Cruthaithe: (2020-08-01)

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
de réir: Jordi Rodon, et al.
Foilsithe / Cruthaithe: (2021-03-01)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
de réir: Jiri Patocka, et al.
Foilsithe / Cruthaithe: (2021-03-01)

SARS-CoV-2: Virology and Drug Repurposing Approaches
de réir: Ratika Rahmasari, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection
de réir: Praveen P. N. Rao, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study
de réir: Ahmad F. Eweas, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach
de réir: Shweta Choudhary, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV‑2 and Potential Mechanisms
de réir: Ana C. Puhl, et al.
Foilsithe / Cruthaithe: (2021-03-01)

High throughput screening for SARS-CoV-2 helicase inhibitors
de réir: Yuka Otsuka, et al.
Foilsithe / Cruthaithe: (2024-09-01)

A review on the use of machine learning techniques in monkeypox disease prediction
de réir: Shailima Rampogu
Foilsithe / Cruthaithe: (2023-01-01)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
de réir: Katarzyna Papaj, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease.
de réir: Katarzyna Papaj, et al.
Foilsithe / Cruthaithe: (2022-01-01)

An overview on monkeypox virus: Pathogenesis, transmission, host interaction and therapeutics
de réir: Shailima Rampogu, et al.
Foilsithe / Cruthaithe: (2023-02-01)

Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of in vitro studies
de réir: Nimer Mehyar
Foilsithe / Cruthaithe: (2023-06-01)

Peroxide derivatives as SARS-CoV-2 entry inhibitors
de réir: Ding-qi Zhang, et al.
Foilsithe / Cruthaithe: (2024-02-01)

Advances in the Development of SARS-CoV-2 Mpro Inhibitors
de réir: Laura Agost-Beltrán, et al.
Foilsithe / Cruthaithe: (2022-04-01)

Recent insights of SARS-CoV-2 potential inhibitors
de réir: Mohd Faheem, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Improved and optimized drug repurposing for the SARS-CoV-2 pandemic.
de réir: Sarel Cohen, et al.
Foilsithe / Cruthaithe: (2023-01-01)

SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System
de réir: Jung Sun Min, et al.
Foilsithe / Cruthaithe: (2021-08-01)